ADAR1 Capital Management LLC Increases Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)

ADAR1 Capital Management LLC lifted its stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 15,557.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,174,313 shares of the company's stock after purchasing an additional 1,166,813 shares during the period. ADAR1 Capital Management LLC owned 3.36% of RAPT Therapeutics worth $1,855,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of RAPT. Geode Capital Management LLC raised its stake in shares of RAPT Therapeutics by 4.9% in the fourth quarter. Geode Capital Management LLC now owns 716,937 shares of the company's stock worth $1,133,000 after buying an additional 33,758 shares during the period. JPMorgan Chase & Co. increased its stake in shares of RAPT Therapeutics by 1,128.3% in the fourth quarter. JPMorgan Chase & Co. now owns 205,164 shares of the company's stock worth $324,000 after purchasing an additional 188,461 shares in the last quarter. Sei Investments Co. bought a new stake in shares of RAPT Therapeutics during the 4th quarter valued at $64,000. Picton Mahoney Asset Management lifted its stake in shares of RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after buying an additional 14,697 shares in the last quarter. Finally, Callan Family Office LLC purchased a new position in shares of RAPT Therapeutics during the 4th quarter valued at $92,000. 99.09% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and set a $10.00 price target on shares of RAPT Therapeutics in a report on Monday, March 10th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, RAPT Therapeutics presently has an average rating of "Hold" and a consensus price target of $4.00.

RAPT Therapeutics Price Performance

Shares of RAPT Therapeutics stock traded up $0.01 during trading on Friday, reaching $0.86. 580,209 shares of the stock traded hands, compared to its average volume of 1,271,194. RAPT Therapeutics, Inc. has a 52-week low of $0.79 and a 52-week high of $9.32. The business has a fifty day simple moving average of $1.15 and a two-hundred day simple moving average of $1.39. The company has a market capitalization of $113.99 million, a price-to-earnings ratio of -0.31 and a beta of -0.29.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last released its quarterly earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.69). On average, research analysts predict that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.